Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04789499 · ClinicalTrials.gov registry record · Phase 2
Smell in Covid-19 and Efficacy of Nasal Theophylline
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT04789499 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 51 participants.
The verdict
NCT04789499, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
Evidence of COVID-19 related anosmia and dysgeusia continues to accumulate daily. Currently, up to 80% of patients report subjective olfactory dysfunction (OD), and prevalence using objective olfactory testing could be even higher. We propose a phase II single-site, double-blinded, placebo-controlled randomized clinical trial to determine the efficacy and safety of intranasal theophylline, a known phosphodiesterase inhibitor in the treatment of asthma, as a possible treatment for COVID-19 related OD. Theophylline has shown benefit in similar clinical trials for post-viral OD.
Interventions
- DRUG Placebo Comparator
- DRUG Theophylline Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2021-03-15 |
| Est. Completion | 2021-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04789499
The ClinicalTrials.gov registry entry for NCT04789499 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Comparator is the first listed.
NCT04789499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04789499 about?
NCT04789499 is a clinical study titled "Smell in Covid-19 and Efficacy of Nasal Theophylline". Evidence of COVID-19 related anosmia and dysgeusia continues to accumulate daily. Currently, up to 80% of patients report subjective olfactory dysfunction (OD), and prevalence using objective olfactory testing could be even higher. We propose a phase II single-site, double-blinded, placebo-control...
What is the current status of trial NCT04789499?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2021-03-15. Estimated completion is 2021-12-30.
What interventions are being tested in trial NCT04789499?
The interventions under investigation include: Placebo Comparator (DRUG), Theophylline Powder (DRUG).
Who is sponsoring clinical trial NCT04789499?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.